Deal Watch: NewAmsterdam To Take On Amgen’s Stalled CETP Inhibitor

New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.